Authors: Hai-Liang Zhang, Bing-Xin Hu, Zhi-Peng Ye, Zhi-Ling Li, Shan Liu, Wen-Qing Zhong, Tian Du, Dong Yang, Jia Mai, Li-Chao Li, Yu-Hong Chen, Xian-Ying Zhu, Xuan Li, Gong-Kan Feng, Xiao-Feng Zhu, Rong Deng
Published: 2024-06-26
DOI: 10.1126/scitranslmed.adk0330
Source: Full article
Targeting ferroptosis for cancer therapy has slowed because of an incomplete understanding of ferroptosis mechanisms under specific pathological contexts such as tumorigenesis and cancer treatment. Here, we identify TRPML1-mediated lysosomal exocytosis as a potential anti-ferroptotic process through genome-wide CRISPR-Cas9 activation and kinase inhibitor library screening. AKT directly phosphorylated TRPML1 at Ser